Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Q2 Revenues Rise 33 Percent on Test Volume

NEW YORK (GenomeWeb) – Cancer genetics diagnostics firm NeoGenomics today said that revenues in the second quarter increased 33 percent year over year while test volume increased 40 percent.

During the three months ended June 30, the Ft. Myers, Fla.-based company recorded $20.7 million in revenues, up from $15.6 million in the year-ago quarter. It beat the consensus analyst estimate of $19.8 million.

The number of tests performed in the quarter was up to 45,475 from 32,519 a year ago.

The company noted that the revenue improvement came despite a reduction in revenues of a little more than $1 million resulting from its "conservative interpretation of the contradictory new National Correct Coding Initiative edits" related to proper billing for FISH testing for Medicare beneficiaries. The Centers for Medicare and Medicaid Services has not yet clarified the issue, and NeoGenomics previously said that for full-year 2014, the NCCI FISH issue could lower revenues by $3 million.

The firm recorded a profit of $274,000, or $.01 per share, in the second quarter, compared to a profit of $273,000, or $.01 per share, in Q2 2013, and matched the average analyst estimate.

Its R&D costs of $633,000 was a 3 percent increase from $616,000 a year ago, while SG&A costs of $9.0 million was a 50 percent increase from $6.0 million in Q2 2013.

NeoGenomics exited the second quarter with $5.0 million in cash and cash equivalents.

Subsequent to the second quarter, the company acquired Path Labs for $6 million.

For the third quarter, NeoGenomics provided revenue guidance of between $22 million and $23.5 million. The firm added that it anticipates a loss of $.01 per share to a gain of $.01 per share.

For full-year 2014, the company said that revenues are estimated to be between $83 million and $86 million. It anticipates EPS at a range of breakeven to $.03.

EPS guidance for the third quarter and for full-year 2014 excludes the impact of any one-time transaction-related expenses from the Path Labs deal, which may be required to be expensed, NeoGenomics said.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.